Strongbridge Biopharma plc (SBBP) Given Consensus Rating of “Buy” by Brokerages
Strongbridge Biopharma plc (NASDAQ:SBBP) has received an average recommendation of “Buy” from the six research firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $13.50.
Several equities analysts have issued reports on the stock. Cantor Fitzgerald assumed coverage on shares of Strongbridge Biopharma in a research note on Tuesday. They issued an “overweight” rating and a $14.00 price objective for the company. Zacks Investment Research cut shares of Strongbridge Biopharma from a “buy” rating to a “hold” rating in a report on Thursday, August 10th. Oppenheimer started coverage on shares of Strongbridge Biopharma in a report on Thursday, August 10th. They issued an “outperform” rating and a $12.00 target price for the company. ValuEngine cut shares of Strongbridge Biopharma from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $18.00 target price on shares of Strongbridge Biopharma in a report on Wednesday, November 15th.
Strongbridge Biopharma (SBBP) traded down $0.45 during midday trading on Tuesday, reaching $6.30. 156,300 shares of the company’s stock traded hands, compared to its average volume of 108,647. The company has a debt-to-equity ratio of -1.89, a current ratio of 4.70 and a quick ratio of 4.61. Strongbridge Biopharma has a one year low of $2.00 and a one year high of $8.85.
Strongbridge Biopharma Company Profile
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.
Receive News & Ratings for Strongbridge Biopharma plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma plc and related companies with MarketBeat.com's FREE daily email newsletter.